MDACC Study No:2006-1018 ( NCT No: NCT00591630)
Title:Zevalin/BEAM/Rituximab vs BEAM/Rituximab with or without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas
Principal Investigator:Issa F. Khouri
Treatment Agent:Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab; Zevalin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the addition of 90Y
Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan)
and rituximab is more effective than the combination of BEAM and rituximab
alone in patients with lymphoma who receive a stem cell transplant.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Carmustine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Stay in hospital 3-4 weeks.
Supported By:N/A
Return Visit:Every 3 months for the first year, then every 6 months.
Home Care:Maintenance Rituximab (dose #5)

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults